References
[1] Serrano C, George S. Gastrointestinal Stromal Tumor: Challenges and Opportunities for a New Decade [J]. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research, 2020, 26(19): 5078-5085.
[2] Kelly C M, Gutierrez Sainz L, Chi P. The management of metastatic GIST: current standard and investigational therapeutics [J]. Journal of Hematology & Oncology, 2021, 14(1): 2.
[3] Nishida T, Blay J-Y, Hirota S, et al. The standard diagnosis, treatment, and follow-up of gastrointestinal stromal tumors based on guidelines [J]. Gastric Cancer: Official Journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association, 2016, 19(1): 3-14.
[4] Brčić I, Argyropoulos A, Liegl-Atzwanger B. Update on Molecular Genetics of Gastrointestinal Stromal Tumors [J]. Diagnostics (Basel, Switzerland), 2021, 11(2): 194.
[5] Yamamoto H, Oda Y. Gastrointestinal stromal tumor: recent advances in pathology and genetics [J]. Pathology International, 2015, 65(1): 9-18.
[6] Mavroeidis L, Metaxa-Mariatou V, Papoudou-Bai A, et al. Comprehensive molecular screening by next generation sequencing reveals a distinctive mutational profile of KIT/PDGFRA genes and novel genomic alterations: results from a 20-year cohort of patients with GIST from north-western Greece [J]. ESMO open, 2018, 3(3): e000335.
[7] Huang W-K, Wu C-E, Wang S-Y, et al. Systemic Therapy for Gastrointestinal Stromal Tumor: Current Standards and Emerging Challenges [J]. Current Treatment Options in Oncology, 2022, 23(9): 1303-1319.
[8] Zhao S, Zhu H, Jiao R, et al. Primary Tumor Resection Improves Survival in Patients with Metastatic Gastrointestinal Stromal Tumors: A Preliminary Population-Based Analysis [J]. Frontiers in Oncology, 2020, 10: 1440.
[9] Ohshima K, Fujiya K, Nagashima T, et al. Driver gene alterations and activated signaling pathways toward malignant progression of gastrointestinal stromal tumors [J]. Cancer Science, Hoboken: Wiley, 2019, 110(12): 3821-3833.
[10] Jennifer Q. Zhang, Benedikt Bosbach, Cristina Antonescu, et a1. Abstract 1038: The KIT-V654A second site mutation confers perinatal lethality and increased oncogenesis in a mouse model of GIST [J].Cancer Research, 2017, 77(13): 1038-1038.
[11] Furitsu T, Tsujimura T, Tono T, et al. Identification of mutations in the coding sequence of the proto-oncogene c-kit in a human mast cell leukemia cell line causing ligand-independent activation of c-kit product[J]. The Journal of Clinical Investigation, 1993, 92(4): 1736-1744.
[12] Palmieri G, Colombino M, Casula M, et al. Molecular pathways in melanomagenesis: What we learned from next-generation se-quencing approaches [J]. Curr Oncol Rep, 2018, 20(11):1-16.
[13] Pham D D M, Guhan S, Tsao H. KIT and melanoma: Biological insights and clinical implications [J]. Yonsei Med J, 2020, 61(1):562-571.
[14] Gupta A, Ma S, Che K, et al. Inhibition of PI3K and MAPK pathways along with KIT inhibitors as a strategy to overcome drug resistance in gastrointestinal stromal tumors [J]. PloS One, 2021, 16(7): e0252689.
[15] Zhao Y, Weng Z, Zhou X, et al. Mesenchymal stromal cells promote the drug resistance of gastrointestinal stromal tumors by activating the PI3K-AKT pathway via TGF-β2 [J]. Journal of Translational Medicine, 2023, 21(1): 219.
[16] Patel S. Exploring novel therapeutic targets in GIST: focus on the PI3K/Akt/mTOR pathway [J]. Current Oncology Reports, 2013, 15(4): 386-395.
[17] Kasireddy V, von Mehren M. Emerging drugs for the treatment of gastrointestinal stromal tumour [J]. Expert Opinion on Emerging Drugs, 2017, 22(4): 317-329.
[18] Courtney K D, Corcoran R B, Engelman J A. The PI3K pathway as drug target in human cancer [J]. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology, 2010, 28(6): 1075-1083.
[19] Klippel A, Kavanaugh W M, Pot D, et al. A specific product of phosphatidylinositol 3-kinase directly activates the protein kinase Akt through its pleckstrin homology domain [J]. Molecular and Cellular Biology, 1997, 17(1): 338-344.
[20] Fujiya K, Ohshima K, Kitagawa Y, et al. Aberrant expression of Wnt/β-catenin signaling pathway genes in aggressive malignant gastric gastrointestinal stromal tumors [J]. European Journal of Surgical Oncology, 2020, 46(6): 1080-1087.
[21] Zeng S, Seifert A M, Zhang J Q, et al. Wnt/β-catenin Signaling Contributes to Tumor Malignancy and Is Targetable in Gastrointestinal Stromal Tumor [J]. Molecular Cancer Therapeutics, 2017, 16(9): 1954-1966.
[22] Li Z, Zhang W, Li Y, et al. TIPE2 acts as a biomarker for GIST risk category and suppresses the viability and invasiveness of GIST cells [J]. Cell & Bioscience, 2018, 8: 62.
[23] Ding J, Xia Y, Yu Z, et al. Identification of upstream miRNAs of SNAI2 and their influence on the metastasis of gastrointestinal stromal tumors [J]. Cancer Cell International, 2019, 19(1): 289.
[24] Ma M-Z, Zhuang C, Yang X-M, et al. CTHRC1 Acts as a Prognostic Factor and Promotes Invasiveness of Gastrointestinal Stromal Tumors by Activating Wnt/PCP-Rho Signaling [J]. Neoplasia (New York, N.Y.), 2014, 16(3): 265-278.e13.
[25] Seo S I, Yoon J-H, Byun H J, et al. HOTAIR Induces Methylation of PCDH10, a Tumor Suppressor Gene, by Regulating DNMT1 and Sponging with miR-148b in Gastric Adenocarcinoma [J]. Yonsei Med J. 2021 Feb; 62(2):118-128.
[26] Mao X, Yang X, Chen X, et al. Single-cell transcriptome analysis revealed the heterogeneity and microenvironment of gastrointestinal stromal tumors [J]. Cancer Science, 2021, 112(3): 1262-1274.
[27] Mu J, Sun P, Ma Z, et al. BRD4 promotes tumor progression and NF-κB/CCL2-dependent tumor-associated macrophage recruitment in GIST [J]. Cell Death & Disease, 2019, 10(12): 935.
[28] Shen C, Han L, Liu B, et al. The KDM6A-SPARCL1 axis blocks metastasis and regulates the tumour microenvironment of gastrointestinal stromal tumours by inhibiting the nuclear translocation of p65 [J]. British Journal of Cancer, 2022, 126(10): 1457-1469.
[29] Wang J, Ren H, Wu W, et al. Immune Infiltration, Cancer Stemness, and Targeted Therapy in Gastrointestinal Stromal Tumor [J]. Frontiers in Immunology, 2021, 12: 691713.
[30] Kerbel RS. Tumor angiogenesis [J]. N Engl J Med, 2008; 358(19):2039-49.
[31] Takahashi R, Tanaka S, Kitadai Y, et al. Expression of vascular endothelial growth factor and angiogenesis in gastrointestinal stromal tumor of the stomach [J]. Oncology, 2003, 64(3): 266-274.
[32] Hu F, Li H, Liu L, et al. Histone demethylase KDM4D promotes gastrointestinal stromal tumor progression through HIF1β/VEGFA signalling [J]. Molecular Cancer, 2018, 17(1): 107.
[33] Wang YM, Gu ML, Ji F. Succinate dehydrogenase-deficient gastrointestinal stromal tumors [J]. World J Gastroenterol, 2015; 21(8):2303-14.
[34] Stockwell, B R. Ferroptosis turns 10: Emerging mechanisms, physiological functions, and therapeutic applications [J]. Cell, 2022, 185(14): 2401-2421.
[35] Wang D, Tang L, Zhang Y, et al. Regulatory pathways and drugs associated with ferroptosis in tumors [J]. Cell Death & Disease, 2022, 13(6): 544.
[36] Hassannia B, Vandenabeele P, Vanden Berghe T. Targeting Ferroptosis to Iron Out Cancer [J]. Cancer Cell, 2019, 35(6): 830-849.
[37] Misra J R, Irvine K D. The Hippo Signaling Network and Its Biological Functions [J]. Annual Review of Genetics, 2018, 52: 65-87.
[38] Thompson B J. YAP/TAZ: Drivers of Tumor Growth, Metastasis, and Resistance to Therapy [J]. BioEssays: News and Reviews in Molecular, Cellular and Developmental Biology, 2020, 42(5): e1900162.
[39] Ravegnini G, Sammarini G, Nannini M, et al. Gastrointestinal stromal tumors (GIST): Facing cell death between autophagy and apoptosis [J]. Autophagy, 2017, 13(3): 452-463.
[40] Gao Z, Li C, Sun H, et al. N6-methyladenosine-modified USP13 induces pro-survival autophagy and imatinib resistance via regulating the stabilization of autophagy-related protein 5 in gastrointestinal stromal tumors [J]. Cell Death and Differentiation, 2023, 30(2): 544-559.